

Appraisal of docetaxel for the treatment of hormone-refractory metastatic prostate cancer
From: Rapu Caroline [caroline.rapu@RCN.ORG.UK]
Sent: 04 November 2005 11:33
To: Alana Miller
Subject: RE: Appraisal of docetaxel for the treatment of hormone-refractory metastatic prostate cancer - RCN Comments

Importance: High

Dear Alana

This is just to let you know that there are no comments to be submitted at this stage on behalf of the Royal College of Nursing on the Assessment Report of the appraisal of docetaxel for the treatment of hormone-refractory metastatic prostate cancer. The RCN looks forward to participating in the next stage of the process.

Thank you for the opportunity to comment.

Please acknowledge receipt.

Regards

Caroline

Caroline Rapu
Project Leader
RCN NICE Portfolio
20 Cavendish Square
London
W1G 0RN

Tel: 020 7647 3603
Fax: 020 7 647 3431

The RCN is consulting on its Professional Membership Structure. Visit www.rcn.org.uk/pdf for more information and let us have your views.

<http://www.rcn.org.uk>

This email is confidential and intended solely for the use of the individual to whom it is addressed. Any views or opinions presented are solely those of the author and do not necessarily represent those of the Royal College of Nursing or any of its affiliates.

If you are not the intended recipient be advised that you have received this email in error and that any use, dissemination, forwarding, printing or copying of this email is strictly prohibited. If you have received this email in error please return it to the sender immediately. The contents of this message may be legally privileged.

Royal College of Nursing of the United Kingdom
20 Cavendish Square
London W1G 0RN
Registered Charity Number: 276435
Tel: +44 (0) 20 7409 3333
Fax: +44 (0) 20 7647 3436

Delivered via MessageLabs
